All In Biotech

Drug Trial Radar · NCT02157506

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure

Last checked: Nov 20, 2026Latest source record: Jul 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

70

Actual

Start

Jun 30, 2014

Primary completion

May 31, 2015

Study completion Jul 31, 2015

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Cardioxyl Pharmaceuticals, Inc
First posted
Jun 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.

Conditions

  • Heart Failure
  • Decompensated Heart Failure
  • Acute Heart Failure

Interventions

  • CXL-1427Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse EventsTime frame: 30 days following the initiation of treatment
  2. Mean Time Averaged Change From Baseline in Adjudicated Pulmonary Capillary Wedge Pressure (PCWP) During InfusionTime frame: Baseline, Hour 2, Hour 4, Hour 6, Hour 8 post infusion
  3. Mean Time-Averaged Change From Baseline in Adjudicated Pulmonary Artery Diastolic Pressure (PAD) During the InfusionTime frame: Baseline, Hour 2, Hour 4, Hour 6, Hour 8 post infusion initiation
  4. Mean Time-Averaged Percent Change From Baseline in Cardiac Index (Fick)Time frame: Baseline, Hour 2, Hour 4, Hour 6, Hour 8 post infusion initiation

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • Cardioxyl Study Site

    Gainesville, Florida

  • Cardioxyl Study Site

    Jacksonville, Florida

  • Cardioxyl Study Site

    Jacksonville, Florida

  • Cardioxyl Study Site

    Macon, Georgia

  • Cardioxyl Study Site

    Baltimore, Maryland

  • Cardioxyl Study Site

    Detroit, Michigan

  • Cardioxyl Study Site

    Newark, New Jersey

  • Cardioxyl Study Site

    Chapel Hill, North Carolina

  • Cardioxyl Study Site

    Cincinnati, Ohio

  • Cardioxyl Study Site

    Columbus, Ohio

  • Cardioxyl Study Site

    Charleston, South Carolina

  • Cardioxyl Study Site

    Nashville, Tennessee

  • Cardioxyl Study Site

    Salt Lake City, Utah

  • Cardioxyl Study Site

    Richmond, Virginia

  • Cardioxyl Study Site

    Bad Neuheim, Germany

  • Cardioxyl Study Site

    Cologne, Germany

  • Cardioxyl Study Site

    Frankfurt, Germany

  • Cardioxyl Study Site

    Göttingen, Germany

  • Cardioxyl Study Site

    Greifswald, Germany

  • Cardioxyl Study Site

    Kiel, Germany

  • Cardioxyl Study Site

    Regensberg, Germany

  • Cardioxyl Study Site

    Amman, Jordan

  • Cardioxyl Study Site

    Irbid, Jordan

  • Cardioxyl Study Site

    Lodz, Poland

  • Cardioxyl Study SIte

    Warsaw, Poland

  • Cardioxyl Study Site

    Warsaw, Poland

  • Cardioxyl Study Site

    Wroclaw, Poland

  • Cardioxyl Study Site

    Kemerovo, Russia

  • Cardioxyl Study Site

    Moscow, Russia

  • Cardioxyl Study Site

    Moscow, Russia

  • Cardioxyl Study Site

    Moscow, Russia

  • Cardioxyl Study Site

    Moscow, Russia

  • Cardioxyl Study Site

    Saint Petersburg, Russia

  • Cardioxyl Study Site

    Saint Petersburg, Russia

  • Cardioxyl Study Site

    Tomsk, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.